ClinicalTrials.gg

Program

ONO-2020

A development code.

Its studies are mostly in Alzheimer Disease, led by Ono Pharmaceutical.

Furthest: phase 2, since Jan 27, 20253 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ono Pharmaceutical31 open or runningphase 2since Jan 27, 2025Aug 11, 2022Dec 31, 2026phase 2 · NCT06803823

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2022First study: phase 1 study in Healthy VolunteersFirst studyNCT05507515 · 132 enrolled · United States
  2. Jan 27, 2025Phase 2 study in Agitation Associated With Alzheimer's Disease DementiaNCT06803823 · 90 planned · Japan
  3. Mar 2, 2025Phase 2 study in Alzheimer DiseaseNCT06881836 · 260 enrolled · United States, Japan

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Agitation Associated With Alzheimer's Disease DementiaNCT06803823

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06881836Alzheimer Disease · United States, Japan2CompletedJul 31, 2026260
NCT06803823Agitation Associated With Alzheimer's Disease Dementia · Japan2RecruitingDec 31, 202690
NCT05507515Healthy Volunteers · United States1CompletedDec 24, 2023132

How it is read

Names in the registry

  • “ONO-2020”, 3 entries

Codes read as this program: ONO2020.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
ONO-2020 (Ono Pharmaceutical): development program | ClinicalTrials.gg